From left to right: Eddie Reed, then-NCI Director Sam Broder, and Brawley in 1991. Reed was receiving an award for his role in developing Taxol.Reed, 60, had liver cancer. Many of us will remember Eddie for his achievements. They were many and spectacular. In the late 1980s, I was the other and younger Black doctor in the Medicine Branch at NCI. I will remember him as a cancer doc, an intense man with high standards.
A Kansas City, Kan., cancer clinic agreed to pay $2.9 million to resolve allegations that it violated the False Claims Act by submitting claims to Medicare, Medicaid, and the Federal Employee Health Benefits Program without providing those drugs and services.
The word “alternative” may soon disappear from the name of the NIH National Center for Complementary and Alternative Medicine.
My name is Clifford Hudis, and I am a medical oncologist at Memorial Sloan Kettering Cancer Center where I am chief of the Breast Medicine Service. I am also professor of medicine at the Weill Cornell Medical College and president of ASCO. I have had an amazing year serving as the president of ASCO, and today I am delighted to welcome you to our society's 50th annual meeting commemorated in recent weeks by both the Congress of the United States and also by our host city, Chicago, and its Mayor, Mr. Rahm Emanuel.
Four Options in Colorectal CancerAnother practice-changing study—CALGB/SWOG 80405— sought to determine whether there is an optimal first-line treatment for patients with untreated metastatic colorectal cancer without KRAS mutations by comparing chemotherapy plus either bevacizumab or cetuximab.
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
FDA approved the Amgen agent Vectibix (panitumumab) for use in combination with FOLFOX as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.
The Special Awards honorees at the 2014 meeting of the American Society of Clinical Oncology are:
Moffitt Cancer Center and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this week announced that they are constructing a bioinformatics framework that would enable a multi-center collaboration.
Douglas Boyd, a professor at MD Anderson, sent his own letter to the American Association of University Professors, responding to DePinho's version of events.
